Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ONCONETIX INC (ONCO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.55-16.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ONCO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Path to profitability and positive cash flow | A primary condition in ONCONETIX INC's published investment case. The stated target is Achieve positive free cash flow by FY27. | Broken | Free cash flow remains negative through FY27 | Free cash flow: $-1.918M FY2026-Q2; GAAP. Published target: Achieve positive free cash flow by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-1,918,067 USD · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making turnaround and commercialization story, not an established compounder. The long-term thesis is in a watch state: the signal recently shifted from cautious to mixed, but financial performance remains weak and management execution is volatile.
The valuation evidence points to ONCO being cheap versus peers, while the expectations gap is negative. Model confidence is low, so that apparent discount is uncertain; the evidence does not show that the market is overlooking a clear improvement in the business.
Near term, results face elevated miss risk, and the supplied financials show revenue of $17,120 in 2026-Q2 alongside an operating loss of $2,730,790. The Realbotix transaction is still pending, while Proclarix disclosures repeat a US marketing expectation without showing product sales or customer milestones. Another reverse split signals continued listing-compliance activity, but the evidence does not establish that the requirement has been met.
Over the next one to three years, the thesis hinges on whether the pending acquisition and Proclarix commercialization produce measurable operating progress. Near term, weaker jobs data could add pressure to cyclical names, while continued earnings strength from sector bellwethers could support the Healthcare backdrop. Misses or lower guidance from those bellwethers would weaken that support.
ONCO remains a speculative, high-risk long-term thesis, with little supplied evidence of commercial traction and substantial execution uncertainty. The sector backdrop offers support, but the company’s own results and delivery remain the central test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable and effective management team |
| A primary condition in ONCONETIX INC's published investment case. The stated target is No further key executive or director departures through FY26. |
| Under Pressure |
| Any additional director or CEO departures before FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress on Realbotix acquisition and partnership | Onconetix is advancing with a strategic partnership and acquisition of Realbotix, both scored 40% progress. | Improving | progress score remains below 40% by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-214200.00 → $-214200.00 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-25 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-26 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-27 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-28 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-29 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-30 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-07-31 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-01 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-02 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-03 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-04 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-05 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-06 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-07 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-08 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-09 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-10 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-12 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-13 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-14 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-15 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-16 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-17 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-18 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-19 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-20 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-21 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-22 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-23 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-24 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-25 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-26 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-27 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-28 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-29 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-30 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-08-31 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-01 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-02 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-03 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-04 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-05 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-06 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-07 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-08 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-09 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-10 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-11 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-12 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-13 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-14 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-15 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-16 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-17 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-18 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-19 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-20 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-21 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-22 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-23 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-24 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-25 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-26 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-27 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-28 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-29 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-09-30 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-01 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-02 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-03 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-04 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-05 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-06 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-07 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-08 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-09 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-10 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-11 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-12 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-13 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-14 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-15 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-16 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-17 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-18 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-19 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-20 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-21 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-22 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-23 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-24 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-25 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-26 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-27 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-28 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-29 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-30 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-10-31 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-11-01 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-11-02 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-11-03 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-11-04 | $-214200.00 | $952,384 | 1 / 1 |
| 2026-11-05 | $-214200.00 | $952,384 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.